Virtual Library

Start Your Search

S. Song



Author of

  • +

    P3.02b - Poster Session with Presenters Present (ID 494)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 2
    • +

      P3.02b-018 - Detection of Epidermal Growth Factor Receptor Mutations in Circulating Cell-Free DNA versus Tumor Biopsy (ID 5550)

      14:30 - 15:45  |  Author(s): S. Song

      • Abstract
      • Slides

      Background:
      Epidermal growth factor receptor (EGFR) mutations are predictive marker of EGFR-tyrosine kinase inhibitor (TKI) therapy. We compared the sensitivity of EGFR mutation detection techniques between matched tumor tissue and peripheral blood sample in patients with lung adenocarcinoma.

      Methods:
      We collected the paired samples from plasma and paraffin-embedded tumor tissue in 202 patients before EGFR-TKIs. DNA extraction was performed using the QIAamp MinElute virus spin kit and EGFR mutation analysis was done by two detection methods. One is the PNAClamp[TM] which is the PNA-based PCR clamping that selectively amplifies only the mutated target DNA sequence as minor portion in mixture with the major wild type DNA sequences. The other is the PANAMutyper[TM] EGFR kit, which use PNA clamping-assisted fluorescence melting curve analysis to perform mutation detection and genotyping. The degree of agreement was evaluated by Cohen's kappa value.

      Results:
      The EGFR mutation rates by PANAMutyper[TM]R and PNAClamp[TM] were 51.0% vs. 47.0% in tissue, and 22.2% vs. 11.4% in plasma sample, respectively. Overall concordance rates and the degree of agreement between tissue and plasma samples was better in PANAMutyper[TM]R (69.3%, k=0.393, p<0.001) than PNAClamp[TM] (62.3%, k=0.211, p<0.001). Sensitivity of plasma EGFR mutations was higher (41.7% vs. 22.1%, p<0.001) and false negative rate was lower in PANAMutyper[TM]R test (58.3% vs. 77.9%, p<0.001). Response to EGFR-TKI was correlated with plasma EGFR mutation by PANAMutyper[TM]R (p=0.025) unlike PNAClamp[TM ](p=0.829).

      Conclusion:
      The sensitivity and concordance rate of PANAMutyper[TM]R test were better than standard PNAClamp[TM] test. So this technique can be useful to detect EGFR mutation in circulating cell-free DNA sample.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      P3.02b-112 - Feasibility of Re-Biopsy in Patients with Non-Small Cell Lung Cancer after Failure of Epidermal Growth Factor Receptor Targeted Therapy (ID 5557)

      14:30 - 15:45  |  Author(s): S. Song

      • Abstract
      • Slides

      Background:
      After failure of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), re-biopsy may be helpful to understand resistance mechanism and guide further treatment decision. However, re-biopsy is still challenging due to several hurdles, such as tissue availability, procedural feasibility, and limited new drugs. The aim of this study was to assess the feasibility of re-biopsy in advanced non-small cell lung cancer (NSCLC) in a real-practice.

      Methods:
      We retrospectively reviewed the clinical and pathologic data of advanced NSCLC patients who had disease progression after previous EGFR-TKI at single institution between January 2015 and February 2016.

      Results:
      Ninety-one patients had disease progression after using EGFR-TKI. Among them, thirty-three patients (36.3%) underwent re-biopsy. re-biopsy was successfully completed for thirty-two patients (97.0%) and only one patient didn’t get malignant cell. Three patients (9.1%) experienced a pneumothorax, however only one patient required closed thoracostomy. After re-biopsy, 27 patients were performed EGFR mutation test. Among 21 patients who had active mutation, the initial mutation was again found in 9 cases (42.9%) while the T790M mutation was found in 6 cases (28.6%). In 4 cases the initial EGFR mutation was no longer found. The patients who had re-biopsy were younger (61.2±9.7 vs. 66.1±10.8 years, p=0.03) and longer response duration (429±383 vs. 265±284 days, p=0.022) than the patients who didn’t.

      Conclusion:
      Re-biopsy in advanced NSCLC is feasible in the real practice especially in younger patient and patients with longer response duration of EGFR-TKI.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.06 - Poster Session with Presenters Present (ID 492)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Trial Design/Statistics
    • Presentations: 1
    • +

      P3.06-005 - Blastomatoid Pulmonary Carcinosarcoma, Combined with Lepidic Adenocarcinoma (ID 5167)

      14:30 - 15:45  |  Author(s): S. Song

      • Abstract
      • Slides

      Background:
      Blastomatoid pulmonary carcinosarcoma is a biphasic tumor with a worse prognosis. The differenial diagnosis is pulmonary blastoma and is often challenging.

      Methods:
      We describe a case of blastomatoid pulmonary carcinosarcoma (BPCS), combined with lepidic adenocarcinoma in a 77-year-old female. Chest computered tomography detected a 7.5cm sized well marginated mass in right upper lobe.

      Results:
      Microscopically, most of the tumor (80%) revealed an immature glandular epithelium resembling high-grade fetal adenocarcinoma expressing epithelial markers and membranous beta-catenin, and blastomatoid spindle cells with extensive necrosis. Both epithelial and spindle cells expressed p53, but not thyroid transcription factor-1 (TTF-1) and Napsin-A. In focal area (20%), lepidic adenocarcinoma (LA) expressing TTF-1 was also noted. Mutation analysis revealed an EGFR mutation within LA, but, no mutation within BPCS.

      Conclusion:
      Blastomatoid carcinosarcoma can coexist with lepidic adenocarcinoma. However, mutation status is different between two components.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.